History

Developed in Adelaide, Australia, around the late 1980s-early 1990s by F. John Ballard, Geoffrey Francis, and colleagues at the CRC for Tissue Growth and Repair, building on CSIRO and University of Adelaide work. They replaced glutamic acid at position 3 with arginine ("R3") and added a 13-amino-acid N-terminal extension, sharply lowering its affinity for IGF-binding proteins so it stays active longer. The Australian biotech GroPep later commercialized it (as LONG R3 IGF-I) as a potent cell-culture supplement for growing recombinant cells.

IGF-1 LR3 is a lab-engineered, longer-acting version of insulin-like growth factor 1 (IGF-1). It is widely sold “for research use only” and promoted for muscle growth, but the human evidence for that use does not exist.

What it is

Native IGF-1 is a 70-amino-acid hormone the body makes mostly in the liver in response to growth hormone. IGF-1 LR3 (“Long R3”) is a modified 83-amino-acid analog: arginine replaces the glutamic acid at position 3, and a 13-amino-acid extension is added to the N-terminus. These changes sharply lower its binding to IGF binding proteins (IGFBPs), the carrier proteins that normally hold most IGF-1 inactive. The result is a molecule that stays free and active far longer than native IGF-1 (hours rather than minutes) and is more potent per dose in laboratory settings.

Worth knowing: LR3 was not developed as a human drug. It was created as a cell-culture supplement to boost cell and protein yields in industrial bioreactors, and that remains its main legitimate, regulated use.

The claims

Marketing material claims IGF-1 LR3 builds muscle (hypertrophy and even hyperplasia), speeds recovery and fat loss, activates muscle satellite cells, and aids tissue repair and “anti-aging.” Sellers often present these as established benefits.

What the evidence actually shows

The mechanism is real: IGF-1 LR3 binds the IGF-1 receptor and switches on the PI3K/Akt and MAPK/ERK pathways that drive protein synthesis and cell proliferation. In cell cultures and rodents, IGF-1 and LR3 reliably promote growth, and LR3 is more potent than the native hormone in those settings.

But there are no controlled human trials of IGF-1 LR3 for muscle, performance, body composition, or recovery. The human IGF-1 data that does exist is for native recombinant IGF-1 (mecasermin), studied in narrow medical conditions — not this analog, not healthy people, and not for athletic goals. Animal potency does not reliably predict human results, and a longer-acting, less-regulated form may behave differently and less predictably in people. As of 2026, the muscle-building case rests on extrapolation, not human outcomes.

Legal and regulatory status

IGF-1 LR3 is not approved by the FDA for human use and is not a dietary supplement. The only FDA-approved IGF-1 product is mecasermin (Increlex), recombinant native IGF-1 approved for the long-term treatment of growth failure in children with severe primary IGF-1 deficiency — a different molecule for a different purpose. IGF-1 LR3 is sold as a “research use only” chemical; that label restricts lawful sale to bona fide laboratory research and is not a green light for human use.

In sport, IGF-1 and its analogs are prohibited at all times (in and out of competition) by the World Anti-Doping Agency under the peptide hormones, growth factors, and related substances class (S2). Athletes in tested programs risk sanctions.

Safety

There is no human safety data for IGF-1 LR3 specifically. Predictable risks come from its biology: because it acts partly like insulin, it can cause hypoglycemia (low blood sugar). Because IGF-1 signaling drives cell growth, there are theoretical concerns about promoting tumor growth and tissue overgrowth with sustained exposure, though this is not quantified for LR3 in humans. Products sold outside the regulated supply chain also carry purity, dosing, and contamination risks. None of this is medical advice.

Bottom line

IGF-1 LR3 has a plausible mechanism and real anabolic effects in animals and cell culture, but zero human trials supporting its marketed uses. It is unapproved for people, banned in sport, and its safety in humans is unknown. The hype runs far ahead of the evidence.

Evidence grade: Animal only.